Biomarker testing should be done on all patients with an initial diagnosis of advanced nonsquamous non–small cell lung cancer, but the testing rates in the real world are lower than they should be, particularly for underserved or minority populations, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Biomarker testing should be done on all patients with an initial diagnosis of advanced nonsquamous non–small cell lung cancer, but the testing rates in the real world are lower than they should be, particularly for underserved or minority populations, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Transcript
What is the real-world utilization of biomarker testing in patients with lung cancer?
Biomarker testing is essential and is recommended for all patients with new diagnosis of nonsquamous non–small cell lung cancer in the stage IV setting. I think the real-world testing rates are lower than they should be. Looking at different studies, you see anywhere from 50% to 60% of patients are receiving adequate testing, and that number may be even lower for populations that are underserved or minority populations.
Are there certain patients with lung cancer who are better candidates for biomarker testing? Are there certain biomarkers that should be tested for first?
I think the reality of it is: for biomarker testing, this should be done for all patients with initial diagnosis of advanced nonsquamous non–small cell lung cancer. In the beginning, we thought that perhaps there were clinical characteristics that might enrich for certain biomarkers, but the more we test, and certainly the number of actionable targets are really increasing. So, it really should be sort of an all-comer population with advanced nonsquamous non–small cell lung cancer.
The way that testing has evolved, it has really evolved from doing single gene testing in a sequential fashion, to try to really do a more broad-based testing all at once with, for example, next-generation sequencing. That can be done with tumor tissue testing, which has been our gold standard. But now we are increasingly incorporating liquid biopsy where you can do next-generation sequencing with liquid biopsy, looking at circulating tumor DNA, and also get really accurate and concordant results with tumor tissue as well.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More